International Journal of Research in Engineering, Science and Management
Volume-1, Issue-10, October-2018
www.ijresm.com | ISSN (Online): 2581-5792

MXD% as a New Hope of Diagnosis of Cancer: A Review

Rudra Prasad Giri[1], Sucheta Ghorai Giri[2]
[1]*Clinical research Manager, Sun Pharmacutical Industries Ltd., Vadodara, India*
[2]*Assistant Professor, Parul Institute of Applied Sciences, Vadodara, India*

***Abstract*—Systemic inflammation and immune responses are reported to be associated with several types of cancer. Here we have reviewed the scope of diagnosis of cancer MXD% which is a part of hematological laboratory test. Among the fractions of WBCs (neutrophils, lymphocytes, monocytes, basophils, and eosinophil) significance NLR and PLR is known but MXD % can also be considered as a biomarker for cancer diagnosis. Several time our laboratory values are neglected but co relating such data with other parameters might help a lot in diagnosis of cancer or other disease. White blood cells are known to be body's first line of defense increase or decrease of certain parameters can help early diagnosis and define a path for further action. Prognostic variables of clinical results in patients with malignancy are a valuable device in the act of drug, particularly in the fields of oncology. In this manner, accessibility of an all-inclusive prognostic factor will help to simplify medical care of malignancy patients. There is ample evidence suggesting that outcome in cancer patients is greatly affected by immune response and pre-treatment measure of inflammatory immune response can be used to independently predict survival of cancer patients. Total and differential WBC count is one of the most easily accessible markers of inflammation and many recent studies in cancers provide evidence that there is an interconnection between pre-treatment WBC counts and overall (OS) and disease free cancer survival (DFS).**

***Index Terms*—Cancer, Cancer Diagnosis, Haematology.**

I. Introduction

An complete blood count (CBC) is a section blood test used to know our general wellbeing and to recognize an extensive variety of disorders. Several components and features of our blood are estimated by a total blood tally test. Regardless of whether we may have a medical condition that calls for further assessment are distinguished by unusual increases or declines in cell counts include as uncovered a complete blood count. As a major aspect of a standard medicinal examination to screen general wellbeing and to screen for a variety of disorders, for example, anemia or leukemia complete blood count is prescribed. A complete blood count is additionally suggested for finding of therapeutic condition on account of encountering weakness, exhaustion, and fever, inflammation, wounding or bleeding. In medical condition to get the cause of any signs and symptoms complete blood count may help to diagnose. At the point when doctor suspects for a disease, the test can likewise help affirm that finding. Physician may utilize complete blood counts to screen your condition, on the off chance that you've been determined to have a blood disorder that influences blood cell counts. Screen therapeutic treatment should be possible through complete blood counts.

The consequences of CBC test which comprise of blood cell count, hemoglobin and hematocrit are connected as they each measure parts of blood cells. When the measures in above stated three areas are lower than normal then it may be concluded as anemia. Fatigue and weakness are felt in the condition of anemia. Anyway sickliness has numerous causes which incorporate low levels of specific vitamins or iron, blood misfortune, or a hidden condition. Underlying therapeutic condition, for example, polycythemiavera or coronary illness could be suspected if blood cell counts that is higher than typical (erythrocytosis), or high hemoglobin or hematocrit levels. On the other hand a medical condition, such as an autoimmune disorder that destroys white blood cells, bone marrow problems or cancer may induce low white blood cell count (leukopenia).Certain medicines additionally can cause white blood cell counts to drop.

For the situation when a blood cell count is higher than ordinary, it very well may be associated for the nearness with an infection or inflammation. Or on the other hand, it could demonstrate for a resistant framework issue or a bone marrow ailment. Drug to drug interaction may demonstrate a high white blood cell. Regularly an indication of a underlying medical condition, or might be an adverse effect from medicine can demonstrate platelet count that is lower than normal (thrombocytopenia) or higher than normal (thrombocytosis). Anyway extra tests to analyze the reason are required if platelet count is outside the typical range.

II. Background

The MXD blood test remains for Mixed Cell Count, and it frames a part of a complete blood count test or a WBC differential tally. A noteworthy part of the complete blood count comprises of the measurement of the concentration of white blood cells, red blood cells, and white blood cell (WBC) count is utilized to quantify the quantity of white blood cell and a WBC differential tally decides the level of each sort of white blood cell present in the blood.

The white platelets (WBCs) are otherwise called leukocytes and frame an essential part of the body's immune system. They're for the most part in charge of ensuring the body against diseases and invading organisms, for example, viruses and bacteria. There are basically five kinds of white blood cell in the body, and these are:

Neutrophils: These cells frame the principal line of barrier when a contamination strikes the body, and they are in charge of destroying and digesting bacterial and parasitic cells.

Lymphocytes: These white blood cells are in charge of making antibodies in the body, to protect it against microorganisms, infections and other destructive trespassers.

Monocytes: These cells help break down bacteria.

Basophils: These cells are in charge of the allergic reaction in the body as they discharge chemicals such as histamine when infectious agents enter the body and therefore help control the body's resistant response.

Eosinophils: The eosinophils work by attacking and destroying parasites, annihilating tumor cells and set off hypersensitive reactions in the body as a response to allergens.

Out of the five kinds of white blood cells, the neutrophils and lymphocytes are viewed as the most imperative, and their levels are estimated independently in a differential WBC count, and the levels of the another three sub-types of white blood cells, i.e., the monocytes, eosinophils, and the basophils are sometimes estimated together in a MXD blood test.

III. What is MXD in CBC?

The Complete blood count (CBC) is an expanded screening test utilized by physicians to decide an individual's general wellbeing status. The test estimates numerous critical conditions identified with the blood cells and generally includes:

a) The white blood cell count.
b) The white blood cell differential count including the MXD blood test result.
c) The red blood cell count.
d) Hematocrit, which is the proportion of the extent of the RBCs to the liquid part of the blood called the plasma.
e) The hemoglobin percentage.
f) The Mean Corpuscular Volume (MCV).
g) The Mean Corpuscular Hemoglobin (MCH).
h) The Mean Corpuscular Hemoglobin Concentration (MCHC).
i) The red cell circulation width (RDW).
j) The platelet count.
k) The Mean Platelet Volume (MPV).

The primary parts of the CBC are the WBC, RBC and platelets' count, and alternate segments depict the attributes of these cells, for example, their size, shading, development, and function.

The normal range for the WBC count is somewhere in the range of 4,300 and 11000 cells for each cubic millimeter of blood. An normal RBC count is by and large thought to be between 4.2 to 5.9 million cells for every cubic millimeter of blood, and the typical range for the platelet count is thought to be between 150,000 to 400,000 cells for each cubic millimeter of blood.

IV. What Does Low or High MXD in Blood Test Mean?

As prior specified, white blood cells frame a critical part of the immunity framework in the body. More often a differential WBC count alongside a physical examination is sufficient for a physician to analyze any underlying disease prompting the irregular WBC levels.

A high MXD blood test esteem shows an immune response to a provocative condition in the body. The monocytes, eosinophils, and basophils have particular capacities to perform in the event of the presence of foreign bodies, for example, microbes, allergens, parasites, or malignancy cells in the body, and an elevated MXD value demonstrates that the immune system is responding to one of these foreign bodies, and may show certain illnesses, for example, asthma, joint pain, leukemia, or tuberculosis.

A low MXD blood test result shows hindered impaired immunity in the body caused by specific sicknesses, for example, tumor, HIV, bone marrow illness/issue, lymphoma, lupus or serious diseases.

V. Role of Eosinophile

Multiple studies have shown an improved prognosis with tumor-associated tissue eosinophilia (TATE) or evidence of eosinophil degranulation in several types of solid tumors, including colon tumors (Pretlow et. al, 1983, Fernandez-Aceneroet al 2000), oral squamous cell carcinoma (SCC, Dortaet al 2002), esophageal SCC (Ishibashi et. al 2006), nasopharyngeal carcinoma (Fujii et. al. 2002), penile cancer (Onoet al 2002), laryngeal carcinoma, pulmonary adenocarcinoma, bladder carcinoma (Costelloet al 2005), and prostate cancer (Luna-Moreet al 2005). This useful impact of eosinophils in differing tumors seems, by all accounts, to be free of other standard prognostic components (e.g., arrange, age, sex, alcohol or tobacco history, histologic evaluating, vascularization, vascular intrusion, and neural attack). Interestingly, TATE is related with poor forecast in Hodgkin lymphoma. Curiously, a substantial bit of the Hodgkin lymphoma tumor mass comprises of an inflammatory infiltrate, recommending noteworthy immune dysregulation by this B-cell tumor (Wasielewski et. al 2000). There have been clashing reports of TATE as a poor prognostic marker in different solids tumors (oral SCC and cervical carcinoma), despite the fact that it has been proposed that this error might be identified with contrasts in study strategies and outline (Horiuchi et. al 1993). There is something like one eosinophil-knockout mouse demonstrates that shows TATE as a risk factor for experimentally induced oral SCCs (da Silva et al 2013).

A. Antitumor Responses

Antitumor cytotoxic reactions by means of degranulation are proposed by the perception of granule proteins in the nearby region of tumors (Caruso et al 2011), yet the tumoricidal impacts of eosinophils are not surely knew. In mice with peripheral blood eosinophilia, there is a considerable lessening in both tumorigenicity and tumor progression associative with an abundant tumor eosinophilia. In correlation, mice with diminished levels of eosinophils (CCL11_/_) or mice that are totally eosinophil inadequate (IL5/CCL11_/_ and DdblGATA) showed elevated tumorigenicity in relationship with reduced tumor eosinophilia (Simson et al 2007). In people, eosinophils are as often as possible watched following immunotherapy with IL-2 (Huland and Huland 1992, Sosman et al 1995), IL-4 (Tepper, Coffman and Leder 1992, Bristol et al 2003), GM-CSF (Schaefer et al 2010), or tumor vaccination (Cormier et al 2006).

B. Necrosis

TATE may grow early and continue all through tumor development yet might be particularly prominent in necrotic regions (Stenfeldt and Wennera 2004). For sure, carcinogenic tissues with related rot can actuate eosinophil relocation in vitro and in vivo (Stenfeldt and Wennera 2004, Geisinger et al 1998). Infusion of melanoma cells into mice causes an abundant eosinophilia inside the necrotic and capsule regions versus territories of viable tumor.

C. Cytokines

Some tumor cells create IL-5, IL-3, eotaxin-1, and thymus and enactment controlled chemokine (TARC or CCL17), which can all things considered follow up on the separation as well as relocation of eosinophils (Fridlender, Simon and Shalit 2003, Dibbert et al 1998, Thielen et al 2008, Lorena et al 2003). In oral cavity SCCs, eosinophils are the primary source of eotaxin (Mattes et al 2003), demonstrating an autocrine-like component for tissue eosinophilia. In a mouse melanoma tumor model, the immunotherapy mediated clearance of CTL-resistant lung tumor by TH2 cells was reliant on eotaxin and STAT. The disposal of these tumors was related with eosinophil degranulation (Rivoltini et al 2003). In another mouse model, tumor cells that were designed to express IL-4 were dismissed or indicated decreased development following implantation into syngeneic have. These IL-4– communicating tumor cells actuated an eosinophil and macrophage-rich tumor invades, and eosinophils were basic for tumor executing (Bristol et al 2003). Predictable with these outcomes, the organization of recombinant IL-4 to patients with tumor in stage 1clinical preliminaries demonstrated proof of eosinophil degranulation in a dosage dose-dependent manner (Tepper, Coffman and Leder 1992). IL-2 immunotherapy is utilized to treat both melanoma and renal cell carcinoma. The antitumor impact of systemic IL-2 treatment is likewise associated with degranulation of eosinophils inside the tumors (Huland and Huland 1992, Sosman et al 1995); this degranulation may happen by means of antibody-dependent mechanisms (Benatar et al 2010). What's more, IL-25 has been appeared to have antitumor action in vivo; IL-25 treatment prompts eosinophilia, which is related with tumor suppression (Lotfi, Lee and Lotze 2010).

D. Damage-Associated Molecular Patterns and Cytotoxic Cellular Receptors

Investigation of eosinophil enlistment in solid tumors has demonstrated that eosinophil tissue penetration is intervened by components discharged straightforwardly from necrotic tumor cells (Ito et al 2007). One of the contributing elements is the eosinophil-inferred cytokine high-versatility group box 1 (HMGB1; Lotfi et al 2009). HMGB1 binds to the receptor for cutting edge glycation final results (RAGE) on eosinophils and triggers eosinophil degranulation (Kataoka et al 2004). Malignant cells are additionally referred to upregulate stress molecules, for example, MHC class I– related chain A (MICA), MICB, and the UL16-binding proteins (ULBP). While the related NKG2D receptor is normally connected with natural killer (NK) cells and NK cell cytotoxic action, eosinophils can likewise be invigorated to express this receptor. Moreover, a blocking anti-NKG2D antibody has been shown to inhibit eosinophil-mediated tumor cytotoxicity (Munitz et al 2005). Eosinophils have been appeared to express 2B4, another receptor that is regularly connected with NK cells. Eosinophil 2B4 enactment brought about cytotoxicity against two tumor cell lines, the mouse mastocytoma P815 and EBV-tainted B-celllines (Legrand et al 2010).

E. Eosinophil Degranulation and Cytotoxicity

Eosinophil lysates are cytotoxic to B16 melanoma cells (Rivoltini et al 1993). In a colon carcinoma cell line, coordinate contact among eosinophils and tumor cells was important to prompt cytotoxicity. This cooperation was appeared to include the adhesion molecule CD11a/CD18 and ECP, EDN, TNF-an, and granzyme A (Rittmeyer and Lorentz 2012). Besides, eosinophil-determined MBP might be available in histologic segments of lung metastases (Rivoltini et al 1993).

F. Connection Between Cancer and Allergy

The connection among sensitivity and disease is questionable. Eosinophils from unfavorably susceptible contributors prompt more elevated amounts of tumor cell apoptosis contrasted and eosinophils from non-hypersensitive donors (Rittmeyer and Lorentz 2012), raising the likelihood that the increased initiation of eosinophils in allergic patients may intercede antitumor impacts. Reliable with this thought, there is some proof to propose a conceivable backwards association with sensitivity for some growth composes, including glioma, pancreatic, and colon tumors; be that as it may, in different malignancies (asthma/lung disease and atopic dermatitis/skin growth), these two pathologies might be emphatically related (Hayashi et al 2017). Generally, the exchange of hypersensitivity and cancer is complex and may include the

relative significance of constant inflammation, immune surveillance, and immune modulatory treatment for hypersensitive ailment.

VI. Monocytes

Monocyte is a sort of Leukocytes, and its estimation is routinely performed in most clinical laboratories around the world. The reason for this examination was to assess whether peripheral monocyte tally could be a valuable indicative and prognostic biomarker for PCa.

Developing proof proposes that irritation may have a noteworthy job in the tumorigenesis and movement of PCa.(De Nunzio et al 2011, De Nunzioet al 2011, Taverna et al 2015) Many systemic inflammation based parameters could recognize PCa and benign prostate illnesses and anticipate the forecast of PCa.(Fujita et al 2012, Langsenlehner et al 2015) Low serum neutrophil tally could foresee a positive prostate biopsy.(Fujita et al 2012) The neutrophil-to-lymphocyte proportion (NLR) appears to speak to an independent prognostic marker in patients with PCa.(Langsenlehner et al 2015) Tumor-associated macrophages (TAMs) are basic modulators of the tumor micro environment, and they are reported to be associated with a poor guess.(Chanmee et al 2014, Nonomura et al 2011) TAMs start from coursing bone marrow-derived monocytic precursors.(Davies et al 2013) Numerous investigations have uncovered that a raised peripheral monocyte count independently predicts unfavorable clinical attributes and poor prognosis in patients with tumors including follicular lymphoma,(Wilcox et al 2012) mantle cell lymphoma,(Von Hohenstaufen et al 2013) lung adenocarcinoma,(Kumagai et al 2014)oropharyngeal cancer,(Huang et al 2015) and hepatocellular carcinoma.(Shen et al 2014) However, regardless of whether peripheral monocyte count plays important roles in the diagnosis and prognosis of PCa has not been accounted for.

VII. Discussion

Notwithstanding the diverse etiology of malignancy, eosinophils are a typical cell invades found in almost all strong tumors and malignancies of epithelial source. Examples of eosinophil-containing cancers in humans(Lee et al 2010) incorporate, and are not restricted to gastrointestinal, uterine, cervical, mammary, bladder, glioblastoma, pancreatic, and oral. (Leeet al 2010, Samoszuk 1997) Although eosinophil infiltration of tumors is common, the cause and consequences (ie, pro-tumorigenicvsanti-tumorigenic) of this recruitment and accumulation are unclear. Ongoing investigations in mouse models of disease and patient biopsies have recommended (Gleich 1990) to some degree free systems possibly connecting eosinophils and malignancy: (Meeusen and Balic 2000) The enrollment of eosinophils is presumably a host fiery reaction to the tumor as a result of cell death/necrosis and/or hypoxia that evokes the arrival of danger associated molecular patterns.(Lotfi, Lee and Lotze 2007) This viewpoint proposes that eosinophils are a part of intrinsic host protection to an apparent risk, prompting redesigning/repair that may increase or decrease tumor development. (Gleich 1990) Tumor penetrating eosinophils are a part of host immune responses that include abilities to polarize T-cell functions, modulate humoral responses, or even be immune suppressive in character. For example, the presence of IDO-positive eosinophils, (Astigiano, Morandiand Costa 2005) release of eosinophil granule proteins,(Walshet al 2011) and the presence of IL-5 (Stathopoulos, Sherrill andKarabela 2010) have all been shown to be protumorigenic, whereas in other instances eosinophils are antitumorigenic.(Simson, Ellyardand Dent 2007) Indeed, animal studies addressing the relative role of eosinophils have been confounding.(Simson, Ellyardand Dent 2007,Wonget al 1999) Regardless of the specific role(s) eosinophils have in cancer, these eosinophil-mediated activities (either remodeling/ repair or immune regulatory) are completely not by stander impacts, and these cells presumably contribute both conceivably noteworthy protumorigenic as well as antitumorigenic exercises.The classic example of eosinophils as a biomarker for disease and severity is in the diagnosis of asthma and asthma exacerbations. In this example, elevated levels of eosinophils in sputum (as detected by hematoxylin and eosin-stained differentials) correlate with disease severity and can be used in the management of patient care.(Nairet al 2009)In any case, novel examines with the capacity to distinguish and evaluate eosinophil activities are presently starting to indicate guarantee as diagnostic tools. For instance, we have illustrated, using a novel anti-eosinophil peroxidase monoclonal antibody (EPX-mAb), that this recognition strategy was equipped for distinguishing tissue penetrating eosinophils in patient biopsies, and in addition proof of degranulation, that was altogether past the capacity to do as such through conventional assessments of hematoxylin and eosin-stained slides. (Willettset al 2011, Protheroe, Woodruff and DePetris2009) In addition, biochemical assays of eosinophil activities (Wu, Samoszuk and Comhair 2000) and eosinophil granule proteins have been used as novel assays to link eosinophil activities to disease severity.

VIII. Conclusion

In conclusion, eosinophils are related with regions of tissue rebuilding and cell turnover amid both homeostasis and infection. In tumors, eosinophils are related with necrotic zones, and there is proof for the cytotoxic impact of eosinophils on tumor cells both in vitro and in vivo. Finally, TATE seems, by all accounts, to be defensive generally, however whether this finding is an immediate connection or only a related uncommon phenomenon needs additionally examines. We trust that this groundwork will urge disease pros to examine the presence of blood as well as tissue eosinophilia amid malignancy advancement, accordingly advancing exploration that endeavors the tumor-controlling capability of eosinophils the betterment of cancer treatment.

REFERENCES

[1] Muhaxheri G, Boras VV, Gabrić D,Terlević D, Vrdoljak B and Filipović M.The Significance of Routine Blood TestsIn Patients With Head and Neck Cancers. *LibriOncol*. 2017; 45(1):19–22.

[2] Incoronato M, Mirabelli P, Catalano O, Aiello M, Parente C, Soricelli A and Nicolai E. CA15-3 is a useful serum tumor marker fordiagnostic integration of hybrid positron emissiontomography with integrated computedtomography during follow-up of breast cancerpatients.*BioMed Central Ltd.*2014, 14:356.

[3] Sozzi G, Conte D, Mariani L, Vullo SL, Roz L, Lombardo C, Pierotti MA,and Tavecchio L.Analysis of Circulating Tumor DNA in Plasma at Diagnosis and during Follow-Up of Lung Cancer Patients. *American Association for Cancer Research Journal*.2001; 61, 4675–4678.

[4] Hinz S, Hendricks A, Wittig A, Schafmayer C, TepelJ,Kalthoff H, Becker T and Röder C. Detection of circulating tumor cells withCK20 RT-PCR is an independent negativeprognostic marker in colon cancer patients– a prospective study.*BioMed Central Ltd.*(2017) 17:53.

[5] Hasija K and Bagga HK. Alterations of Serum Cholesterol and Serum Lipoprotein in Breast Cancer of Women. *Indian Journal of Clinical Biochemistry*, 2005, 20 (1)61-66.

[6] Haber DA and Velculescu VE. Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA. *Cancer Discov*. 2014; 4(6): 650–661.

[7] Sun H, Yin C, Liu Q,Wang F, Yuan C.Clinical Significance of Routine Blood Test-Associated Inflammatory Index in Breast CancerPatients. *Medical Science Monitor*.2017; 23: 5090-5095.

[8] Jenkins P &Freeman S. Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer.*Annals of Oncology.2008;* 20: 34–40.

[9] Zelig U, Barlev E, Bar O, Gross I, Flomen F, Mordechai S, Kapelushnik J, Nathan I, Kashtan H, Wasserberg N and Madhala-Givon O. Early detection of breast cancer using total biochemical analysis of peripheral bloodcomponents: a preliminary study. *BioMed Central.*2015; 15:408

[10] DePrimo SE, Wong LM, Khatry DB, Nicholas SL, Manning WC, Smolich BD, O'Farrell AM and Cherrington JM. Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy forbiomarker identification. *BioMed Central.*2003, 3:3

[11] Shrivastava S, Singh N, Nigam AK, ChandelSS,Shrivastava R, Kumar S.Comparative study of hematological parameters along with effect ofchemotherapy and radiotherapy in different stages of breast cancer. *International Journal of Research in Medical Sciences*.2017; 5(1):311-315.

[12] Omoti CE, Osime E. Haemorheological Changes in Cancerpatients on Chemotherapy. *Pak J Med Sci*.2007; 23: 3.

[13] Taylor A and Pollack MA.Hemoglobin Level and Tumor Growth.*American Association for Cancer Research Journal. 1941.*

[14] Ghosh I ,Bhattacharjee D , Das AK,Chakrabarti G, Dasgupta A, Dey SK.Diagnostic Role of Tumour Markers CEA, CA15-3, CA19-9and CA125 in Lung Cancer.Ind J Clin Biochem.2013; 28(1):24–29.

[15] Padma R and Sundaresan S. Haematological and Biochemical Changes In Pre and Post Treatment of Buccal Mucosa Carcinoma Patients. International Journal of Pharmaceutical Sciences and Research. 2016; 7(7): 3002-3006.

[16] Davis BP and Rothenberg ME.Eosinophils and Cancer.American Association for Cancer Research.2014; 2(1); 1–8.

[17] Jain A, Bobdey S, Sathwara J, Ganesh B, Saoba S, Khan A. Role of monocyte and lymphocyte counts in prognosis of cervical cancer. International Journal of Reproduction, Contraception, Obstetrics and Gynecology.2016; 5(7):2243-2249.

[18] Jacobsen E A, Helmers R A, Lee J J and Lee N A. The expanding role(s) of eosinophils in health and disease.The American Society of Hematology. 2012; 120(19).

[19] Wang YQ, Zhu YJ, Pan JH, Xu F, Shao XG, Sha JJ, Liu Q, Huang YR, Dong BJ, Xue W. Peripheral monocyte count: an independentdiagnostic and prognostic biomarker for prostatecancer – a large Chinese cohort study. Asian Journal of Andrology. 2017. 19, 579–585.

[20] Hayashi T, Fujita K, Tanigawa G, Kawashima A, Nagahara A, Ujike T, Uemura M, Takao T, Yamaguchi S and Nonomura N. Serum monocyte fraction of white blood cells is increased in patients with high Gleason score prostate cancer, 2017, 8, (21),35255-35261.

[21] Stone K D, Prussin C, Metcalfe D, MdB.IgE, mast cells, basophils, and eosinophils.Elsevier.2010.